Filtered By:
Cancer: Cancer
Therapy: Statin Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 598 results found since Jan 2013.
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
CONCLUSION: Relugolix suppressed testosterone and was generally well tolerated when given with concomitant CV agents.TRIAL REGISTRATION: Clinical Trial ID NCT03085095.PRIOR PRESENTATION: Data presented at 15th Annual Genitourinary Cancers Symposium; February 17-19, 2022, San Francisco, CA, USA [Abstract 101, Poster board E11]. The published abstract from this presentation can be found at https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.101 .PMID:37713020 | DOI:10.1007/s12325-023-02634-7
Source: Adv Data - September 15, 2023 Category: Epidemiology Authors: Neal D Shore Bryan A Mehlhaff Michael S Cookson Daniel R Saltzstein Ronald Tutrone Bruce Brown Sophia Lu Mark Fallick Sarah Hanson Fred Saad Source Type: research
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Current Pharmaceutical Design - September 15, 2023 Category: Drugs & Pharmacology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
Exploring Sorafenib and Simvastatin Combination for Ferroptosis-Induced Cancer Treatment: Cytotoxicity Screening, In Vivo Efficacy, and Safety Assessment
In this study, we conducted a screening of drug combinations, including sorafenib (SOR) with simvastatin (SIM), phenethyl isothiocyanate, and trigonelline, in MDA-MB-231, A549, and HeLa cells to assess their cytotoxicity. The SOR-SIM combination exhibited a synergistic effect in MDA-MB-231, A549, and HeLa cells, with calculated CI values of ~ 0.66, 0.53, and 0.59, respectively. Furthermore, co-treatment with ferrostatin-1 resulted in a concentration-dependent increase in the IC50 values. Additionally, SOR + SIM demonstrated a significant reduction in GSH levels, an increase in MDA levels, and mitochondrial membrane depolar...
Source: Cancer Control - September 11, 2023 Category: Cancer & Oncology Authors: Kaushik Kuche Vivek Yadav Meet Patel Rohan Ghadi Sanyog Jain Source Type: research
Statin use and risk of colorectal cancer in patients with inflammatory bowel disease
EClinicalMedicine. 2023 Aug 24;63:102182. doi: 10.1016/j.eclinm.2023.102182. eCollection 2023 Sep.ABSTRACTBACKGROUND: Statin use has been linked to a reduced risk of advanced colorectal adenomas, but its association with colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) - a high risk population for CRC - remains inconclusive.METHODS: From a nationwide IBD cohort in Sweden, we identified 5273 statin users and 5273 non-statin users (1:1 propensity score matching) from July 2006 to December 2018. Statin use was defined as the first filled prescription for ≥30 cumulative defined daily doses and follow...
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Jiangwei Sun Jonas Halfvarson David Bergman Fahim Ebrahimi Bjorn Roelstraete Paul Lochhead Mingyang Song Ola Ol én Jonas F Ludvigsson Source Type: research
Rhabdomyolysis-induced acute kidney injury after administration of a red yeast rice supplement: A case report
CONCLUSION: We speculate that statins, the main lipid-lowering component of RYR, or a combination of statins and abiraterone, will increase the risk of rhabdomyolysis.PMID:37637685 | PMC:PMC10450378 | DOI:10.12998/wjcc.v11.i23.5547
Source: Clinical Prostate Cancer - August 28, 2023 Category: Cancer & Oncology Authors: Ya-Han Wang Si-Shuo Zhang Hai-Tao Li Hong-Wei Zhi Hong-Yun Wu Source Type: research
Towards Evidence-Based Implementation of Pharmacogenomics in Southern Africa: Comorbidities and Polypharmacy Profiles across Diseases
We describe comorbidities in 3997 patients from Malawi, South Africa, and Zimbabwe. These patient cohorts were included in pharmacogenomic studies of anticoagulation, dyslipidemia, hypertension, HIV and breast cancer. The 20 topmost prescribed drugs in this population were identified. Using the literature, a list of pharmacogenes vital in the response to the top 20 drugs was constructed leading to drug-gene pairs potentially informative in translation of pharmacogenomics. The most reported morbidity was hypertension (58.4%), making antihypertensives the most prescribed drugs, particularly amlodipine. Dyslipidemia occurred ...
Source: Topics in HIV Medicine - August 25, 2023 Category: Infectious Diseases Authors: Nyarai Desiree Soko Sarudzai Muyambo Michelle T L Dandara Elizabeth Kampira Dirk Blom Erika S W Jones Brian Rayner Delva Shamley Phumla Sinxadi Collet Dandara Source Type: research
A Systematic Review and Meta-analysis on the Role of Statins in the Prevention of Mortality Following Pancreatic Cancer
CONCLUSION: Statins reduce the risk of mortality in patients with PC. However, no significant relation has been observed in RCTs. Therefore, it is necessary to be cautious in interpreting the results.PMID:37622694 | DOI:10.2174/1871520623666230824095226
Source: Cancer Control - August 25, 2023 Category: Cancer & Oncology Authors: Khatereh Anbari Mehdi Mohammadian Amiri Saeid Heidari-Soureshjani Catherine Mt Sherwin Karamali Kasiri Source Type: research
Towards Evidence-Based Implementation of Pharmacogenomics in Southern Africa: Comorbidities and Polypharmacy Profiles across Diseases
We describe comorbidities in 3997 patients from Malawi, South Africa, and Zimbabwe. These patient cohorts were included in pharmacogenomic studies of anticoagulation, dyslipidemia, hypertension, HIV and breast cancer. The 20 topmost prescribed drugs in this population were identified. Using the literature, a list of pharmacogenes vital in the response to the top 20 drugs was constructed leading to drug-gene pairs potentially informative in translation of pharmacogenomics. The most reported morbidity was hypertension (58.4%), making antihypertensives the most prescribed drugs, particularly amlodipine. Dyslipidemia occurred ...
Source: Topics in HIV Medicine - August 25, 2023 Category: Infectious Diseases Authors: Nyarai Desiree Soko Sarudzai Muyambo Michelle T L Dandara Elizabeth Kampira Dirk Blom Erika S W Jones Brian Rayner Delva Shamley Phumla Sinxadi Collet Dandara Source Type: research
